Magle Chemoswed Holding
8.05 SEK
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Magle Chemoswed Holding
| Q1/24 | Q2/24 | Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 38.2 | 46.0 | 64.6 | 87.2 | 236.0 | 81.4 | 52.4 | 71.5 |
| EBITDA | 7.0 | 5.3 | -55.2 | 101.7 | 58.9 | 18.8 | -20.6 | 33.4 |
| EBIT | 4.2 | 1.3 | -67.9 | 85.6 | 23.2 | 2.1 | -29.0 | 20.3 |
| EBIT-% | 10.9 % | 2.9 % | -105.0 % | 98.1 % | 9.8 % | 2.6 % | -55.4 % | 28.3 % |
| Profit before taxes | 3.5 | -0.0 | 10.7 | -2.0 | 12.2 | -1.1 | -27.9 | 2.9 |
| Net income | 2.9 | 0.2 | 9.6 | -0.7 | 11.9 | -1.2 | -27.8 | 3.1 |